EVLO Evelo Biosciences Inc.

8.16
+0.14  (+2%)
Previous Close 8.02
Open 8.05
Price To Book 1.9
Market Cap 260057078
Shares 31,869,740
Volume 5,298
Short Ratio
Av. Daily Volume 46,089

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 initial data due 2Q 2019.
EDP1066
Psoriasis or atopic dermatitis
Phase 2a dosing has commenced - noted January 28, 2019 with initial data due 2H 2020.
EDP1503 and KEYTRUDA (pembrolizumab)
Melanoma
Phase 1b initial data due 2H 2019.
EDP1815
Psoriasis and Atopic Dermatitis
Phase 1/2 trial initiation announced January 4, 2019 with initial data due 1H 2020.
EDP1503 and KEYTRUDA (pembrolizumab)
Colorectal cancer; Triple-negative breast cancer

Latest News

  1. Evelo Biosciences to Present at 39th Annual Cowen & Co. Health Care Conference
  2. Evelo Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights
  3. Evelo Biosciences to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 14, 2019
  4. Evelo Biosciences Announces Dosing of First Patient in Investigator-Sponsored Phase 2a Clinical Trial of EDP1503 in Combination with KEYTRUDA® in Patients with Metastatic Melanoma
  5. Evelo Biosciences Announces Dosing of First Patient in Phase 1/2 Clinical Trial of EDP1503 in Combination with KEYTRUDA® (pembrolizumab) in Multiple Oncology Indications
  6. Evelo Biosciences to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
  7. Evelo Enters into Clinical Trial Collaboration Agreement with Merck
  8. Evelo Biosciences Announces First Dosing in Phase 1b Clinical Trial of EDP1815 in Psoriasis and Atopic Dermatitis
  9. Report: Developing Opportunities within Evelo Biosciences, ADMA Biologics, Karyopharm Therapeutics, Pingtan Marine Enterprise, Rosetta Stone, and Williams Companies — Future Expectations, Projections Moving into 2018
  10. Evelo Biosciences to Present at Upcoming Investor Conferences in November
  11. Evelo Biosciences Reports Third Quarter 2018 Financial Results and Recent Business Highlights
  12. Evelo Biosciences' Potential Is 'Significant,' Says Bullish Morgan Stanley